Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Bevacizumab HAIC in Advanced HCC
NCT05975463Phase 2Not yet recruiting
- Start
- Sep 2023
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in hepatocellular carcinoma (HCC). Planned start Sep 2023; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05975463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975463.